Archford Capital Strategies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Archford Capital Strategies’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$608K	Sell	2,019 -17	-0.8%	-$5.13K	0.06%	221
2026 Q1	$674K	Buy	2,036 +12	+0.6%	+$4.08K	0.08%	205
2025 Q4	$805K	Hold	2,024	–	–	0.09%	182
2025 Q3	$923K	Buy	2,024 +7	+0.3%	+$2.85K	0.11%	174
2025 Q2	$658K	Sell	2,017 -2	-0.1%	-$553	0.08%	194
2025 Q1	$545K	Buy	+2,019	New	+$519K	0.08%	196
2023 Q1	–	Sell	-1,041	Closed	-$247K	–	277
2022 Q4	$247K	Sell	1,041 -3	-0.3%	-$640	0.06%	248
2022 Q3	$209K	Buy	+1,044	New	+$199K	0.05%	261

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Archford Capital Strategies's ALNY Position: Q2 2026 in Review

Archford Capital Strategies reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.83% in Q2 2026, selling an estimated $5.13K and leaving 2,019 shares worth $608K. The position accounts for 0.06% of the portfolio, ranked #221.

Archford Capital Strategies first reported a position in ALNY in Q3 2022 and has held it in 8 quarters since. The position peaked at $923K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Archford Capital Strategies held 2,019 shares of Alnylam Pharmaceuticals worth $608K as of Q2 2026.
Archford Capital Strategies sold 17 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $5.13K.
Alnylam Pharmaceuticals made up 0.06% of Archford Capital Strategies's portfolio in Q2 2026, its #221 holding.
Archford Capital Strategies first reported a position in Alnylam Pharmaceuticals in Q3 2022 and has held it in 8 quarters since.
Archford Capital Strategies's Alnylam Pharmaceuticals position peaked at $923K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Archford Capital Strategies's 13F filing for Q2 2026, filed 17 Jul 2026.